Cempra, Inc. (CEMP) Lowered to Hold at Zacks Investment Research

Zacks Investment Research lowered shares of Cempra, Inc. (NASDAQ:CEMP) from a buy rating to a hold rating in a research report report published on Monday.

Receive News & Ratings for Cempra Inc. Daily

Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

According to Zacks, “Cempra Holdings, LLC is a pharmaceutical company engaged in developing antibiotics for the treatment of bacterial infectious diseases. It focuses on developing antibiotics for treating respiratory tract, skin and skin structure infections and to target the growing problem of antimicrobial resistance. Cempra Holdings, LLC is headquartered in Chapel Hill, North Carolina. “

Several other research firms have also commented on CEMP. Jefferies Group LLC reissued a hold rating and issued a $3.00 target price on shares of Cempra in a report on Thursday, May 25th. Roth Capital lowered shares of Cempra from a buy rating to a neutral rating and decreased their target price for the company from $8.00 to $4.00 in a report on Thursday, August 10th. ValuEngine lowered shares of Cempra from a sell rating to a strong sell rating in a report on Friday, June 2nd. Stifel Nicolaus reissued a hold rating and issued a $4.00 target price on shares of Cempra in a report on Thursday, August 10th. Finally, Vetr raised shares of Cempra from a buy rating to a strong-buy rating and set a $4.86 target price on the stock in a report on Monday, May 1st. Four investment analysts have rated the stock with a sell rating, twelve have given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. Cempra has an average rating of Hold and an average target price of $11.38.

Cempra (NASDAQ CEMP) traded down 2.344% during mid-day trading on Monday, reaching $3.125. 188,053 shares of the company were exchanged. The company’s 50 day moving average price is $4.13 and its 200-day moving average price is $3.85. Cempra has a 12-month low of $2.55 and a 12-month high of $26.95. The stock’s market capitalization is $164.08 million.

Cempra (NASDAQ:CEMP) last issued its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.09. Cempra had a negative net margin of 560.40% and a negative return on equity of 53.99%. The business had revenue of $0.86 million during the quarter, compared to analysts’ expectations of $3.58 million. During the same quarter in the previous year, the company earned ($0.51) EPS. The business’s revenue was down 74.9% on a year-over-year basis. On average, equities research analysts forecast that Cempra will post ($1.00) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “[[title]]” was first published by [[site]] and is the sole property of of [[site]]. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at [[permalink]].

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CEMP. Asset Management One Co. Ltd. bought a new position in Cempra during the first quarter worth about $106,000. Voya Investment Management LLC increased its position in Cempra by 34.1% in the second quarter. Voya Investment Management LLC now owns 23,006 shares of the biotechnology company’s stock worth $106,000 after buying an additional 5,848 shares during the last quarter. Janney Montgomery Scott LLC increased its position in Cempra by 35.6% in the second quarter. Janney Montgomery Scott LLC now owns 25,900 shares of the biotechnology company’s stock worth $119,000 after buying an additional 6,800 shares during the last quarter. UBS Asset Management Americas Inc. bought a new position in Cempra during the first quarter worth about $140,000. Finally, LMR Partners LLP bought a new position in Cempra during the second quarter worth about $149,000. Institutional investors own 52.39% of the company’s stock.

Cempra Company Profile

Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).

Get a free copy of the Zacks research report on Cempra (CEMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com